JESSICA NAPIER: Open Payments
NPI 1720674187 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,659 in 122 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $888 · 2025 $2,659
Food & beverage: $2,548Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $588 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $433 |
| Neurocrine BioSciences, Inc. | 13 | $410 |
| Teva Pharmaceuticals USA, Inc. | 13 | $376 |
| Alkermes, Inc. | 13 | $257 |
| E.R. Squibb & Sons, L.L.C. | 5 | $214 |
| Janssen Pharmaceuticals, Inc | 5 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $90 |
| Bausch Health US, LLC | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, ARISTADA, COBENFY, AUSTEDO XR, UZEDY, INVEGA SUSTENNA.
Industry payments across AZ — which companies pay providers there.
